Track the 参天製薬株式会社 share price and the full management transaction log of the company, a listed equity based in Japan. Shares are quoted on JP JP, under the oversight of EDINET (Japan FSA). Operating in the Banks sector, 参天製薬株式会社 has recorded 25 insider filings. Market capitalisation: €40,269.7bn. The latest transaction was reported on 8 October 2025 (Holding update). Among the most active insiders: Silchester International Investors LLP. The full history is openly available.
25
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
n/a
n/a
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate 参天製薬株式会社 Buy (bullish), based on 11 analysts. Average price target: JP¥3,596.
19Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,175 of 28,105 companies
57.0
score / 100
Value
37
Quality
77
FCF yld-59%
Earn yld6.0%
EV/EBITDA·
ROE9.4%
Gross mgn·
Net mgn32%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Santen Pharmaceutical Co., Ltd. is a Japanese company specializing in the pharmaceutical sector, providing health and eye care products. It is listed on the Tokyo Stock Exchange under the symbol XTKS.